Tumor necrosis factor-alpha (TNF-alpha) is a chemokine secreted by T cells which is thought to play a critical role in the pathophysiology of psoriasis. The monoclonal antibody, infliximab, complexes with TNF-alpha, rendering it inactive. A recent clinical trial has reported the clinical benefit and safety of infliximab in moderate to severe plaque psoriasis. We report a case of rapid response and clinical benefit using infliximab in severe pustular psoriasis of von Zumbusch.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1046/j.1365-4362.2002.01543.x | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!